Introduction diabetes mellitus is the most common metabolic. Metformin improves overall survival of colorectal cancer patients with diabetes. The meta analysis showed that therapy with metformin use was associated with decreased. Background a growing body of evidence has suggested that metformin potentially reduces the risk of cancer. As such, a significant association 31% reduction between metformin use and cancer incidence pancreatic and hcc was reported in a metaanalysis of 11 studies consisting of 4042 patients with cancer and diabetes. Association of metformin and risk of liver cancer are mainly studied in animal and observational human studies. The beneficial effects of metformin on cancer prevention and.
Reduced risk of colorectal cancer with metformin therapy in. We conducted searches of pubmed, embase and the cochrane central register of controlled trials to identify studies evaluating risk or survival data of ovarian cancer in diabetic patients taking metformin versus those not. Therefore, the present metaanalysis on epidemiological studies was performed to explore this issue. Repositioning metformin for cancer prevention and treatment. Epidemiological, preclinical and clinical evidence supports the use of metformin as a cancer therapeutic. We conducted a comprehensive literature search for all pertinent studies addressing metformin use. Efficacy and safety of metformin for patients with type 1. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. This drug is inexpensive, has an excellent safety profile, and can be safely combined with other antidiabetes agents 2. Pubmed, embase, and the cochrane library databases were searched for observational. Sep 18, 2019 the search strategy used the following terms.
Dec 23, 2011 metformin does not appear to activate ampk directly, but inhibits mitochondrial complex i of the respiratory chain, leading to an increase in the amp. Metformin improves overall survival of colorectal cancer patients with. Association between metformin and cancer incidencemortality across selected studies was computed as a summary relative risk srr with. Pubmed, embase, and the cochrane library databases were searched for observational studies. Metformin may be able to extend health and lifespans in the general population.
Reduced risk of colorectal cancer with metformin therapy. Metformin is a wellestablished, effective agent for the management of type 2 diabetes mellitus. Effect of metformin on mortality among diabetic cancer patients. Diabetic population has a higher risk of colorectal cancer crc incidence and mortality than nondiabetics.
The metaanalysis was conducted in accordance with the guidelines for the metaanalysis of observational studies in epidemiology moose and the prisma statement 18, 19. The ability of metformin to lower circulating insulin may be particularly important for the. Metformin x breastcancer x diabetesmellitus x survival x metaanalysis abstract background. Understanding the benefit of metformin use in cancer. Association of metformin use with cancer incidence and. Our meta analysis indicated that metformin was negatively associated with the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of overall cancer, liver cancer and breast cancer. We performed a systematic search of pubmed, embase, cochrane, and web. Dunn4, leslie ford5, andrea decensi6, and eva szabo7 abstract. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of anysite and sitespecific cancers in patients with diabetes. The meta analysis was performed on 6 studies of a total of 1,579 metformin users with lung cancer. Building the clinical evidence on metformin and cancer.
The effect of metformin therapy on incidence and prognosis in. The aim of the study was to evaluate the association between metformin use and cancer incidence and mortality in diabetic patients. Therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. Metformin therapy has been associated with a reduced risk of endometrial cancer, liver cancer, lung cancer, pancreatic cancer, and colorectal cancer, but not related with breast cancer. Jul 31, 2012 observational studies have suggested that metformin decreases the incidence of several common cancers. Research article cancer prevention research metformin and. Apr 18, 2018 previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer ec, while the results have been inconsistent. Pdf cancer risk in diabetic patients treated with metformin. We conducted a search on medline, embase, and the cochrane library for relevant studies published before may 2014 based on metformin and diabetes mellitus, type 1.
A metaanalysis revealed that cancer patients with preexisting diabetes have an increased risk of mortality compared with. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. Pubmed, embase, and cochrane library were searched till july 1, 2016. Metformin users also had reduced cancer compared to nondiabetics rate ratio 0. The beneficial effects of metformin on cancer prevention. Metformin, cancer, molecular action, clinical evidence. Metformin, an antidiabetic drug, has emerged as a new adjunctive strategy for different cancer types, including endometrial cancer. Metformin reduces allcause mortality and diseases of. Biguanides have been developed for the treatment of hyperglycemia and type 2 diabetes.
We conducted a metaanalysis to analyse the effect of metformin on survival of pancreatic cancer patients at various stages. However, limitations include heterogeneous comparator types, absent cancer data from two trials, and short followup, especially for mortality. The effect of metformin therapy on incidence and prognosis. A metaanalysis revealed that cancer patients with preexisting diabetes have an increased risk of mortality compared with those without diabetes. Reduced risk of lung cancer with metformin therapy in. Methodsprincipal findings we performed a search of medline, embase, isi web of science, cochrane library, and clinicaltrials. Metformin use is associated with better survival of breast. Metformin for liver cancer prevention in patients with type 2 diabetes.
By interrogating the gene expression omnibus geo for microarray expression data, we identified eight eligible submissions, representing five different studies, that employed various conditions. A metaanalysis demonstrated that metformin appeared to have a direct antihepatocellular carcinoma hcc effect in animal models. Obesity and its metabolic complications, including diabetes, have been associated with an increased risk of several cancers. Research article metformin and cancer risk in diabetic patients. However, findings regarding breast cancer have been mixed. Research design and methods the pubmed and sciverse scopus databases were searched to identify studies that examined the effect of metformin therapy on colorectal cancer among patients with type 2 diabetes. For each metaanalysis on the association between metformin use and cancer risk or survival outcomes, the summary effect was synthesized. Pdf metformin and cancer risk in diabetic patients. Our metaanalysis indicated that there was no association of metformin use with prostate cancer risk, which further enriched the knowledge of relationship between metformin therapy and cancer development. Metaanalysis showed that the risk of developing lung cancer was lower in metformin users than in those without metformin or0.
We performed a comprehensive literature search and metaanalysis. Research paper the clinical effect of metformin on the. The search was carried out on observational studies and trials, without language restrictions. We performed a comprehensive literature search and meta analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using pubmed, isi web of science, embase, and the cochrane library until may 2009. Metformin for liver cancer prevention in patients with type 2. Metformin has been associated with cancer risk reduction in recent epidemiologic studies in diabetic patients 3446. The os meta analysis was performed following the appropriate cochrane guidelines 22. The pleiotropic anticancer effects of mtf on cancer cells have not been fully explored yet. Therefore, the present meta analysis on epidemiological studies was performed to explore this issue. Meta analysis suggests benefits of metformin therapy in patients with comorbid kidney or heart disease. Frontiers the potential effect of metformin on cancer. Previous metaanalyses have shown that the antidiabetic agent metformin is. Background and aim although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma.
Metformin for cancer prevention and therapy for colon, pancreatic, breast, liver and bladder cancer6. Monotherapy with metformin versus sulfonylureas and risk of. Original article the effects of metformin on ovarian cancer. The role of metformin in crc prognosis is still controversial. Cancer risk in diabetic patients treated with metformin. Results of the meta analysis showed that the incident cancer risks were significantly decreased for cancers of the lung in metformin users, compared with non metformin users or0. Diabetics on metformin have less cardiovascular disease than other diabetics. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Metformin use is associated with reduced incidence and improved survival of endometrial cancer. The effect of metformin therapy on incidence and prognosis in prostate cancer. In the mean time longterm rcts are called for to confirm the clinical benefit of metformin. Diabetics on metformin have less cancer than nondiabetics and other diabetics.
We conducted a comprehensive literature search for all pertinent studies addressing metformin use and. In summary, this large metaanalysis of cohort studies did not find an association between metformin use and risk of prostate cancer. Improved understanding of these issues will increase the chances for successful application of metformin as an inexpensive, welltolerated, and effective anticancer agent. It decreases the production of excess sugar by the liver and helps maintain normal blood sugar levels. The meta analysis aims to investigate whether metformin improves the survival of diabetic crc patients. Summary effect estimates were derived using a randomeffects meta analysis model. The association between metformin and the lung cancer risk of patients with type 2 diabetes mellitus t2dm remains controversial. A summary of the main characteristics for studies of breast, colorectal and prostate cancer is presented in table 1table 1, and a table of study characteristics for. Metformin use is associated with reduced incidence and. Survival benefits of metformin for colorectal cancer patients with diabetes. We performed a metaanalysis of randomized clinical trials to investigate the effect of metformin on biomarkers associated with breast cancer outcomes and to explore the doseresponse relationship. The summary risk estimates for the association between metformin.
Jul 19, 2017 we conducted a meta analysis to analyse the effect of metformin on survival of pancreatic cancer patients at various stages. Metformin and colorectal cancer risk in diabetic patients metformin and colorectal cancer risk in diabetic patients. Metformin improves overall survival of colorectal cancer. This metaanalysis was performed to provide the evidence of clinical efficacy and safety of metformin in t1dm. Breast cancer is a leading cause of cancer mortality in developed countries. The summary rr for exposure to metformin versus su was the measure of interest. Oct 27, 2017 a meta analysis of studies comparing outcomes between metformin users and non metformin users for cancers treated curatively at an early stage found that, in colorectal cancer above left, metformin use was associated with longer recurrence free survival, overall survival and cancer specific survival.
International journal of molecular sciences article metaanalysis of microarray expression studies on metformin in cancer cell lines hansjuergen schulten 1, and sherin bakhashab 2,3 1 center of excellence in genomic medicine research, department of medical laboratory technology, faculty of applied medical sciences, king abdulaziz university, p. Metformin appears to extend health and life spans independent of its effect on diabetes. Thus, the potential use of metformin as a novel cancer prevention strategy has generated much. Recently, metformin, the most widely prescribed biguanide, has emerged as a potential anticancer agent. The os metaanalysis was performed following the appropriate cochrane guidelines 22. Monotherapy with metformin versus sulfonylureas and risk of cancer in. Original article the effects of metformin on ovarian.
Metformin, a biguanide derived from the french lilac, has become the preferred firstline therapy for the treatment of type 2 diabetes 1. Metformin and lung cancer risk of patients with type 2. Furthermore, a meta analysis showed a significantly lower risk of colorectal cancer with metformin therapy among patients with type 2 diabetes, suggesting a potential role of metformin in chemoprevention for cancer potentially across indications. Metformin reduces allcause mortality and diseases of ageing. We performed a comprehensive literature search and meta analysis. Metaanalysis of studies using metformin as a reducer for liver. Metformin, an insulinlowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. Jan 01, 2019 therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. We performed a comprehensive literature search and metaanalysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using pubmed, isi web of science, embase, and the cochrane library until may 2009. Observational studies have suggested that metformin decreases the incidence of several common cancers.
Previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer ec, while the results have been inconsistent. Several studies have demonstrated that metformin mtf acts with variable efficiency as an anticancer agent. As such, a significant association 31% reduction between metformin use and cancer incidence pancreatic and hcc was reported in a meta analysis of 11 studies consisting of 4042 patients with cancer and diabetes. Metformin in cancer treatment and prevention annual. Apr 26, 2016 metformin or also called glucophage, is an oral prescription medication used to treat type 2 diabetes. Overall cancer incidence was reduced by 31% summary relative risk srr. Metformin x breastcancer x diabetesmellitus x survival x meta analysis abstract background. The summary risk estimates for the associations of metformin treatment with. A metaanalysis yunliangtang,1 lingyanzhu,1 yuli,2 jiaoyu,1 jiaowang,1 xiangxiazeng,1. However, the evidence for a cancer preventive effect for metformin has not been consistently demonstrated.
Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. The inclusion criteria in the metaanalysis are as follows. Introduction metformin 1,1dimethylbiguanide is the most widely. Although a metaanalysis demonstrated that metformin was significantly associated with a lower incidence of ovarian cancer in patients with diabetes 30, studies on the use of metformin to prevent ovarian cancer in. Metformin anticancer treatment or cancer prevention. As a result, it has become the most widely prescribed antidiabetes drug worldwide. Eligible trials also showed no significant effect of metformin on allcause mortality. Indeed, a number of preclinical studies support this pleiotropic effect of metformin on cancer. Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent. Metformin is a safe, effective and welltolerated agent, which is recommended as the first line oral hypoglycemic in treatment of newly diagnosed type ii diabetes. Preclinical evidence suggests that metformin appears to inhibit the. Objective the potential therapeutic effects of metformin on several cancers were reported. Association of the metformin with the risk of lung cancer. Meireles and others published effects of metformin on endometrial cancer.
Metformin efficacy and safety for colorectal polyps. The effect of metformin on survival of patients with. Metaanalysis of studies using metformin as a reducer for. Research article metformin and cancer risk and mortality.
1560 247 492 176 1007 37 1342 1119 1660 1498 1315 122 1315 463 1093 1281 497 1569 1312 1094 1004 1227 1031 804 1472 1084 454 1302 176 1110 970 462 485 762 60 1202 36 463 1216 1401